#EASD26 - Twitter Hashtag

about 6 hours ago

チルゼパチドとエロラリンチリドの併用"eloraTZP"がチルゼパチド単独に圧倒的な減量効果出したのね😳 リリー強いな〜 #EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes - https://t.co/R7ixIsj0I9

0

1

0

1

258

Michel Doepke

@doepke_michel

about 10 hours ago

$ABBV $GUBRA Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at #EASD26. $NVO $LLY $VKTX https://t.co/y1L5Mu3tY4

0

9

0

2

2K

Michel Doepke

@doepke_michel

1 day ago

$NVO Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis at #EASD26. $LLY https://t.co/g8lGW0Rr0k

1

5

0

1K

UAB Comprehensive Diabetes Center @UABDiabetes

2 days ago

UCDC Director Dr. Anath Shalev presented at the @Innodiagroup Symposium on T1D Therapies in conjunction with #EASD26 in Milan, Sept. 28. As part of the Beta Cell Health session, she discussed how #TIX100 targets #TXNIP directly to protect beta-cell health & islet function.

UABDiabetes's tweet photo. UCDC Director Dr. Anath Shalev presented at the
@Innodiagroup Symposium on T1D Therapies in conjunction with #EASD26 in Milan, Sept. 28. As part of the Beta Cell Health session, she discussed how #TIX100 targets #TXNIP directly to protect beta-cell health & islet function. https://t.co/q6mEiMiIGV

0

2

0

103

Medical Product Outsourcing

@MPOmagazine

2 days ago

Dexcom data points to a CGM awareness gap, and room to grow: https://t.co/VN1mZ4tEjD @EASDnews #EASD26 #Dexcom #Diabetes

0

35

Medical Product Outsourcing

@MPOmagazine

2 days ago

.@AbbottNews study links CGM use to lower mortality in type 2 diabetes: https://t.co/Ohu02pTm4c @EASDnews #T2D #Type2Diabetes #EASD26

MPOmagazine's tweet photo. .@AbbottNews study links CGM use to lower mortality in type 2 diabetes: https://t.co/Ohu02pTm4c @EASDnews #T2D #Type2Diabetes #EASD26 https://t.co/2nBwh7eo6G

0

47

Lilly Medical US

@LillyMedical

6 days ago

We're in Milan and excited to connect with you at #EASD26. We're so grateful for the opportunity to learn alongside you and be part of the conversations shaping the future of care. Join Lilly Medical at booth K.01. Learn more: https://t.co/cErqZXedtH

0

231

Michel Doepke

@doepke_michel

14 days ago

$NVO #UBT251 - one of the most promising obesity assets currently in #NovoNordisk's pipeline. Upcoming events: CMD in London September 21, #EASD26 presentation September 30.

doepke_michel's tweet photo. $NVO #UBT251 - one of the most promising obesity assets currently in #NovoNordisk's pipeline. Upcoming events: CMD in London September 21, #EASD26 presentation September 30. https://t.co/Gq4PdYth4x

Aktieland

@Aktieland

15 days ago

Mark September 30. 👀 EASD will feature Phase 2 data on #UBT251 — a triple GLP-1/GIP/GCG receptor agonist — in both obesity and type 2 diabetes. Two presentations on the same day. One to watch closely. $NVO

Aktieland's tweet photo. Mark September 30.

👀 EASD will feature Phase 2 data on #UBT251 — a triple GLP-1/GIP/GCG receptor agonist — in both obesity and type 2 diabetes. Two presentations on the same day. One to watch closely. $NVO https://t.co/f8nsgS0YzE

2

8

0

2

5K

2

14

1

0

5K

Michel Doepke

@doepke_michel

15 days ago

$NVO to share real-world and clinical data including Wegovy® pill, and cardiometabolic pipeline progress with next-generation amylin treatments at #EASD26 https://t.co/1LvbibgbKE

0

5

0

1K

Top Tweets for #EASD26

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users